NovoCure Limited

NASDAQ:NVCR

Medical - Instruments & Supplies

Healthcare
$10.73 -19.66%

-$3.51 today

Market cap
$1.25B
Beta
0.92
P/E (TTM)
-9.5
EPS (TTM)
-$1.52
52W Low $9.82High $18.92

Volume 1.41M

Average 1.52M

NVCR Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

NovoCure LimitedNASDAQ: NVCR

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $174.06M rose 12.3% year over year, ahead of the +8.5% change in trailing-twelve-month revenue. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $740.8M (+13.0%) for the fiscal year ending Dec 2026, a step up from the +8.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$174.06M-0.2% QoQ
Last fiscal yearDec 2025
$655.35M+8.3% YoY
LTMMar 2026
$674.41M+8.5% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.3%+8.6%-3.7 pp
1 year+8.3%+13.0%+4.8 pp
3-year CAGR+6.8%+10.8%+4.0 pp
5-year CAGR+21.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
655.35M USD
Year-over-year change
+8.3%
4-year CAGR
+5.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How NVCR compares with its peers on the latest reported figures

  • NVCR's LTM Mar 2026 revenue of $674.41M is the highest of the 4 companies compared; the peer median is $90.44M.
  • Its year-over-year change of +8.5% is the lowest of 3, against a peer median of +43.0%.
  • Over three fiscal years its annual growth of +6.8% compares with a peer median of +30.0%.
NVCR Competitors Peer median
Revenue for NVCR and competitors
Company Period LTM YoY 3-year CAGR
NVCRNovoCure LimitedLTM Mar 2026$674.41M +8.5%+6.8%
NPCENeuroPace, Inc.LTM Mar 2026$99.53M +18.1%+30.0%
DCTHDelcath Systems, Inc.LTM Mar 2026$90.44M +67.9%+215.3%
PLSEPulse Biosciences, Inc.LTM Jun 2026$1.19M —-20.6%
Peer median (excluding NVCR) $90.44M+43.0%+30.0%

Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue535.03M537.84M509.34M605.22M655.35M
Cost of Revenue114.88M114.87M128.28M137.18M166.88M
Gross Profit420.15M422.97M381.06M468.04M488.47M
Gross Margin78.5%78.6%74.8%77.3%74.5%
Research & Development201.3M206.09M223.06M209.65M224.54M
Selling, General & Admin263.18M306.41M390.87M428.89M417.73M
Operating Expenses464.49M512.5M614.67M638.54M642.27M
Depreciation & Amortization10.25M10.62M10.97M11.24M17.2M
EBITDA(38.38M)(67.89M)(177.45M)(109.58M)(119.05M)
EBITDA Margin-7.2%-12.6%-34.8%-18.1%-18.2%
Operating Income(44.33M)(89.52M)(232.87M)(170.5M)(153.8M)
Operating Margin-8.3%-16.6%-45.7%-28.2%-23.5%
Interest Income1.1M15.79M46.04M51M18.11M
Interest Expense8.84M8.11M4.91M11.66M0
Other Income / Expenses(7.74M)7.68M41.13M39.33M17.55M
Income Before Tax(52.08M)(81.85M)(191.74M)(131.16M)(136.25M)
Pre-Tax Margin-9.7%-15.2%-37.6%-21.7%-20.8%
Income Tax Expense6.28M10.69M15.3M37.47M(23K)
Net Income(58.35M)(92.53M)(207.04M)(168.63M)(136.23M)
Net Margin-10.9%-17.2%-40.6%-27.9%-20.8%
EPS (Basic)(0.56)(0.88)(1.95)(1.56)(1.22)
EPS (Diluted)(0.56)(0.88)(1.95)(1.56)(1.22)
Weighted Avg Shares103.43M104.66M106.39M107.83M111.47M
Weighted Avg Shares (Diluted)103.43M104.66M106.39M107.83M111.47M

NovoCure Limited

NASDAQ:NVCR

Intrinsic Alpha fair value

Locked

Current Price

$10.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.